Since ubiquitination is the major way of regulating protein degradation, we can develop drugs targeting the ubiquitination pathway to improve the ubiquitination of PD-L1 to make PD-L1 more stable, thus reducing the overall level of PD-L1 in tumor cells and improving the effect of immunotherapy. This evidence concerns the gene CD274 and neoplasm.